Interest is growing in the role of viral infections and their association with adverse pregnancy outcomes. The trophoblast is permissive to viruses, but little is known about their impact on the placenta. We previously established that viral single stranded RNA (ssRNA), a Toll-like receptor 8 (TLR8) agonist, induces a restricted trophoblast pro-inflammatory cytokine/chemokine response by upregulating the secretion of interleukin (IL)-6 and IL-8. In parallel, the type I interferon, IFNbeta, is produced and acts back on the cell in an autocrine/paracrine manner to trigger caspase-3-dependent apoptosis. In this study, we sought to extend these findings by determining the mechanisms involved, examining whether viral ssRNA could induce a trophoblast antiviral response, and evaluating the influence of viral ssRNA on pregnancy outcome using a mouse model. Viral ssRNA induced human first-trimester trophoblast inflammation, type I interferon production, an antiviral response, and apoptosis in both a TLR8/MyD88-dependent and -independent manner. Furthermore, administration of viral ssRNA to pregnant mice induced placental caspase-3 activation, a pro-inflammatory cytokine/chemokine, type I interferon, and antiviral response as well as immune cell infiltration. Thus, ssRNA viral infections may compromise pregnancy by altering placental trophoblast survival and function through both TLR8 and non-TLR8 signaling pathways, leading to immune changes at the maternal-fetal interface.
INTRODUCTION
Infections can adversely influence pregnancy by gaining access to gestational tissues, such as the placenta [1] , and triggering inflammatory and/or apoptotic responses [2, 3] . Strong clinical links exist between bacterial infection and preterm birth [1, [4] [5] [6] , and other complications, such as preeclampsia, may also have an underlying infectious element [7] [8] [9] [10] [11] . Less is known about how viruses impact pregnancy, but their role in maternal complications is being realized based on results from clinical and experimental studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In addition to the potential for fetal infection and developmental complications, single stranded RNA (ssRNA) viral infections, including adenovirus, Epstein-Barr virus, cytomegalovirus, parvovirus, influenza, and rubella, have been associated with preterm delivery, second-trimester miscarriage, still birth, and preeclampsia [10, 12, 14, 15, [19] [20] [21] [22] [23] [24] .
While the trophoblast is permissive to viral infections [7] , our understanding of the placental responses generated, or of the mechanisms involved, is still lacking. One way in which infection-associated inflammation and/or apoptosis occurs in the trophoblast is through activation of Toll-like receptors (TLRs). However, the type of pathogen or pathogen-associated molecular pattern (PAMP)-and, therefore, the specific TLR activated-may have a significant impact on the type of response generated by the placenta [3] . We previously established that ssRNA, a TLR8 agonist, induces a specific response in human first-trimester trophoblast cells. Viral ssRNA triggers a very restricted pro-inflammatory cytokine response by upregulating the cell's secretion of interleukin (IL)-6 and IL-8. In parallel, the type I interferon IFNb is produced and acts back on the cell in an autocrine/paracrine manner to induce caspase-3-dependent apoptosis [25] . In the present study, we sought to extend these findings by determining the mechanisms involved, examining whether viral ssRNA could induce an antiviral response in the trophoblast, and evaluating the influence of viral ssRNA on pregnancy outcome using a mouse model.
MATERIALS AND METHODS

Trophoblast Cell Lines
The human first-trimester trophoblast cell line, HTR-8/SVneo, was a kind gift from Dr. Charles Graham (Queens University, Kingston, ON, Canada) [26] . These cells behave similarly to primary cells isolated from first-trimester placental villi [27] [28] [29] and express cytokeratin and HLA-G [26, 30, 31] . HTR8 cells were cultured in RPMI 1640 (Gibco), supplemented with 10% fetal bovine serum (Hyclone), 10 mM Hepes, 0.1 mM Minimal Essential Medium nonessential amino acids, 1 mM sodium pyruvate, and 1000 U/ml/1000 lg/ml penicillin/streptomycin (Gibco), and were maintained at 378C with 5% CO 2 . In previous studies, we have shown that HTR8 cells express TLR8 and its adapter protein, MyD88 [25, 32] . HTR8 cells were stably transfected with the pDeNy plasmid containing the human MyD88 dominant negative (MyD88-DN) as previously described [29, 33, 34] and were cultured in full growth medium with 1 lg/ml of puromycin (InvivoGen). HTR8 cells were also stably transfected with the pZERO plasmid containing the human HA-tagged TLR8DTIR (InvivoGen). The TLR8DTIR acts as a TLR8 dominant negative (TLR8-DN), because the TIR domain has been deleted. Briefly, cells were transfected overnight with 2 lg of DNA using FuGENE 6 (Roche Diagnostics). Following transfection, cells were allowed to recover in growth media for 24 h, after which selection for stable expression was performed using 250 lg/ml of Zeocin (InvivoGen). For experiments, wild-type, MyD88-DN, and TLR8-DN HTR8 cells were seeded in 60-mm tissue culture dishes (BD Biosciences) in full growth medium overnight, after which medium was changed into serum-free OptiMEM (Life Technologies). Cells were then treated with or without viral ssRNA (ssRNA40/LyoVec; InvivoGen) at 5 lg/ml for 12 or 24 h, after which RNA or protein was extracted from the cells and cell-free supernatants collected.
Animal Studies
Pregnant adult Hsd:ICR (CD-1) mice (age, 8-12 wk; Harlan Laboratories) were obtained at Embryonic Day (E) 13.5. All animals were maintained in the Yale University School of Medicine Animal Facility under specific pathogenfree conditions, and all procedures were approved by the Yale University Institutional Animal Care and Use Committee. Viral ssRNA was reconstituted in sterile PBS at a concentration of 5 lg/300 ll, 10 lg/300 ll, 50 lg/300 ll, or 100 lg/300 ll. Each mouse was injected intraperitoneally at E16.5 with 300 ll of either PBS (control) or viral ssRNA. All mice were kept in separate cages and monitored for any sign of preterm birth, as evidenced by the delivery of one or more pups within 24 h. After 24 h, mice were euthanized, and tissue samples were collected. For cytokine mRNA and caspase-3 protein studies, placental tissue was harvested, snap-frozen, and kept in À808C for further analysis. For histology and immunostaining, tissues were fixed in paraformaldehyde and paraffin-embedded. Sections of placental tissue (section thickness, 5 lm) were then subjected to hematoxylin-and-eosin (H&E) staining or immunostaining for the pan-immune cell marker CD45 (rat anti-mouse CD45; catalog no. 550539; BD Pharmingen) with hematoxylin counterstaining. Counting of CD45-positive cells was performed in three randomly selected fields (magnification 203) in each placental region of interest (labyrinth and junctional zone) and the mean used for analysis (n ¼ 3 per condition).
RNA Isolation and Quantitative Real-Time PCR
Total RNA from the trophoblast cell lines and mouse placental tissue was extracted using TRIzol, chloroform, and 2-propanol according to the manufacturer's instructions (Life Technologies) as previously described [35, 36] . Total RNA concentrations were measured at A260 using a NanoDrop (Thermo Scientific) and stored at À808C. For the analysis of mRNA expression levels, quantitative real-time PCR (qPCR) was performed using the KAPA SYBR FAST qPCR kit (Kapa Biosystems) on the Bio-Rad CFX Connect Real-Time System (Bio-Rad) as previously described [35] [36] [37] . All primer sequences used are shown in Table 1 . Data were normalized to the housekeeping gene, GAPDH, analyzed using the D-DCT method and presented as fold-change in the expression of gene of interest relative to the no-treatment or PBS control.
Secreted Cytokine Analysis
After treatment of wild-type, MyD88-DN, or TLR8-DN trophoblast cells with or without viral ssRNA, cell-free supernatants were collected by centrifugation at 400 3 g for 5 min and stored at À808C until analysis was performed. The concentrations of IL-6 and IL-8 were measured by ELISA (Enzo Life Sciences).
Caspase-3 Activity Assay
To measure apoptosis, the Caspase-Glo Assay (Promega) was used to measure the activity of caspase-3 in human trophoblast and mouse placental lysates as previously described [25, 38] . Luminescence was measured using a TD-20/20 luminometer (Turner Designs) in triplicate and data recorded as relative light units.
Statistical Analysis
Data are expressed as the mean 6 SEM of pooled experiments. Statistical significance (P , 0.05) was determined by the Student t-test using GraphPad Prism (GraphPad Software).
RESULTS
Viral ssRNA Induces a Pro-Inflammatory and Antiviral Response in Human Trophoblast Cells
We previously reported that viral ssRNA triggers human HTR8 trophoblast cells to secrete elevated levels of the proinflammatory cytokines/chemokines IL-6 and IL-8 and the type I interferon IFNb [25] . The first objective of the present study was to further evaluate the effects of viral ssRNA on interferon and the antiviral response downstream of interferon at the transcriptional level. As shown in Figure 1 , treatment of HTR8 trophoblast cells with viral ssRNA significantly increased mRNA expression for the pro-inflammatory cytokines/chemokines, IL6 by 8.3-fold and IL8 by 1.3-fold; the type I interferons, IFNA by 2.6-fold and IFNB by 3.6-fold; the interferon-inducible antiviral factors, OAS by 1.4-fold, MxA by 2.5-fold, and APOBEC3G by 2.2-fold; and the antiviral/ antimicrobial peptide, SLPI, by 2.3-fold. Treatment of the cells with viral ssRNA had no significant effect on the mRNA expression levels of the antimicrobial peptide HBD1, and HBD2 mRNA was undetectable (Fig. 1 ).
Viral ssRNA Induces a Trophoblast Pro-Inflammatory and Antiviral Response in a TLR8/MyD88-Dependent and TLR8/MyD88-Independent Manner
Having established that the HTR8 trophoblast cells generate a pro-inflammatory, type I interferon, and antiviral response after treatment with viral ssRNA, our next objective was to determine the mechanisms involved. In humans, viral ssRNA activates the TLR8/MyD88 signaling pathway [39] . As shown in Figure 2 , inhibition of MyD88 ( Fig. 2A) and TLR8 (Fig. 2B ) function using dominant negatives significantly reduced viral ssRNA-induced trophoblast IL-6 secretion but had no significant effect on ssRNA-induced IL-8 secretion. The impact of disabling the TLR8/MyD88 signaling pathway was then further investigated at the mRNA level. As shown in Figure 3 , the presence of the TLR8-DN significantly inhibited ssRNAinduced upregulation of mRNA for IL6, IL8, IFNA, and SLPI when compared to wild-type cells. The presence of the MyD88-DN also significantly inhibited ssRNA-induced upregulation of mRNA for IL6, IL8, and IFNA, but the upregulation of SLPI mRNA in response to ssRNA was not significantly reduced (Fig. 3) . In contrast, viral ssRNA-induced upregulation of IFNB, OAS, MxA, and APOBEC3G mRNA was not significantly changed by the presence of either the TLR8-DN or MyD88-DN (Fig. 3) .
FIG. 1. Viral ssRNA induces a pro-inflammatory and antiviral response in a human trophoblast cell line. HTR8 cells were incubated with or without viral ssRNA for 12 h, and qPCR was performed for the proinflammatory cytokines IL8 and IL6; the type I interferons IFNA and IFNB; the antiviral factors OAS, MxA, and APOBEC3G (APO); and the antimicrobial peptides SLPI, HBD1, and HBD2. Bar chart shows the fold-change in mRNA levels relative to the untreated control (*P , 0.05) from eight independent experiments. ns, not significant; ud, undetectable.
FIG. 2. Viral ssRNA-induced trophoblast IL-6 secretion is TLR8/MyD88-dependent, whereas IL-8 secretion is TLR8/MyD88-independent. Wild-type trophoblast cells (HTR8) and HTR8 cells stably transfected to express either a MyD88-DN (n ¼ 6; A), or a TLR8-DN (n ¼ 3; B) were treated with or without ssRNA for 24 h. Bar charts show the fold-change (FC) in IL-6 and IL-8 secretion relative to the untreated control. *P , 0.05 relative to the wild-type control.
EFFECT OF VIRAL ssRNA ON TROPHOBLAST FUNCTION Viral ssRNA Induces Trophoblast Caspase-3 Activity in a TLR8-Independent Manner
We previously reported that viral ssRNA triggers human HTR8 trophoblast cells to undergo caspase-3-associated apoptosis, indirectly through the production of IFNb [25] . Similar to ssRNA-induced trophoblast IFNB expression (Fig.  3) , viral ssRNA-induced trophoblast caspase-3 activity was unaffected by the presence of the TLR8-DN (Fig. 4) , suggesting both responses are occurring in a TLR8-independent manner.
Administration of Viral ssRNA to Pregnant Mice Induces Placental Apoptosis, Inflammation, and a Type I Interferon Response
The final objective was to determine whether the effects of viral ssRNA found in human first-trimester trophoblast cells were mirrored in vivo. For this, mice were injected on E16.5 with either viral ssRNA (5-100 lg) or PBS. Because no induction of preterm birth occurred with ssRNA administration at any of the doses tested, tissues were harvested after 24 h. No differences in uterus weight, fetal weight, or fetus numbers were observed at any of the ssRNA doses when compared to the PBS controls (Supplemental Fig. S1 ; all Supplemental Data are available online at www.biolreprod.org). Thus, we continued our studies using the highest ssRNA concentration (100 lg), and placental histology revealed an effect of this viral ssRNA treatment. As shown in Figure 5A , morphological analysis of H&E-stained placenta showed evidence of cell loss localized to the placental junctional zone in mice exposed to viral ssRNA, but this was not observed in placenta from the PBS-treated mice. This suggested that viral ssRNA might be inducing placental cell death in vivo. Furthermore, significantly more CD45-positive cells were found in the labyrinth and the junctional zones of the placenta after treatment with viral ssRNA relative to the PBS controls (Fig. 5, B and C) , suggesting immune cell infiltration. To address these observations further, we measured the levels of caspase-3 activity and the levels of inflammatory and antiviral markers in the placentas. As shown in Figure 6A , caspase-3 activity was significantly increased in placentas from viral ssRNA-treated mice (100 lg) compared to the PBS control. Lower ssRNA concentrations also increased placental caspase-3 activity (Supplemental Fig. S2) . At the mRNA level, expression of the chemokine KC (mouse homologue of IL-8) was significantly increased compared to the PBS control (Fig. 6B) . Expression of the pro-inflammatory cytokine IL-6 and the type I interferons IFNA and IFNB were also significantly increased by ssRNA compared to the PBS control, although only modestly (Fig. 6B) . Moreover, ssRNA significantly increased placental expression of the antiviral genes OAS, MxA, APOER3, and SLPI, but not the beta defensins, BD1 and BD2, when compared to the PBS controls (Fig. 6B) .
DISCUSSION
Not all women with a viral infection will have an adverse pregnancy outcome, but some viral infections, including ssRNA viruses, can be detected in the amniotic fluid or gestational tissues and have been linked to an increased risk for pregnancy complications, including preterm birth miscarriage, still birth, and preeclampsia [10, 12, 14, 15, [19] [20] [21] [22] [23] [24] . Moreover, delivery of PAMPs to pregnant animals can trigger preterm birth and other adverse pregnancy outcomes, and TLRs have been implicated in its pathogenesis [16, 17, [40] [41] [42] [43] [44] [45] . Indeed, although infections are thought to influence pregnancy primarily by triggering inflammation [2, 3] , elevated placental trophoblast apoptosis is also POTTER ET AL. seen in pregnancies complicated with preeclampsia, intrauterine growth restriction, and preterm birth [46] [47] [48] [49] [50] . Some viruses have been associated with chronic placental inflammation [51] ; others have been shown to trigger placental trophoblast dysfunction by reducing trophoblast invasion and inducing apoptosis [31, [52] [53] [54] [55] . We previously demonstrated that viral ssRNA indirectly FIG. 5 . Histological analysis of placentas from pregnant mice treated with viral ssRNA. A) Morphological analysis of H&E-stained placenta showed evidence of cell loss (arrowheads) localized to the placental junctional zone (see higher magnification in ii) in mice exposed to viral ssRNA (100 lg), whereas this was not observed in placenta from the PBS-treated mice (i). Images are representative from one placenta from PBS-treated (n ¼ 6) and ssRNAtreated (n ¼ 8) mice. B) Representative example of immunostaining for the immune cell marker, CD45, in the placental labyrinth. C) Immunostaining revealed an significantly elevated number of CD45-positive cells in both the labyrinth and the junctional zones of the placenta after treatment with viral ssRNA relative to the PBS controls. Jctz, junctional zone; Lab, labyrinth. Bars ¼ 500 lm for whole placenta (A), 100 lm for higher magnification (i and ii); and 50 lm (B). *P , 0.05.
FIG. 6.
Administration of viral ssRNA to pregnant mice increases placental caspase-3 activity and pro-inflammatory cytokine/chemokine type 1 IFN and antiviral gene expression. Pregnant mice were treated with PBS (n ¼ 6) or viral ssRNA at 100 lg (n ¼ 8). Placental tissues were analyzed for caspase-3 activity (A) and for KC, IL-6, IFNA, IFNB, OAS, MxA, APOBEC3 (APO), BD1, and BD2 mRNA (B) by qPCR. Bar chart shows the fold-change in mRNA levels relative to the PBS control. ns, not significant. *P , 0.05 relative to the PBS control.
EFFECT OF VIRAL ssRNA ON TROPHOBLAST FUNCTION mediates human trophoblast apoptosis through an inflammatory mechanism [25] . In the present study, we show that viral ssRNA triggers a human first-trimester trophoblast pro-inflammatory, antiviral, and pro-apoptotic response through TLR8-dependent and -independent signaling pathways. Furthermore, we report, to our knowledge for the first time, the impact viral ssRNA has on pregnancy outcome and placental function using a mouse model.
Having previously shown that viral ssRNA increases human trophoblast secretion of IL-6, IL-8, and IFNb [25] , we sought to further examine the antiviral response. In addition to upregulating IL-6, IL-8, and IFNB at the mRNA level in the trophoblast, viral ssRNA also upregulated IFNA and the antiviral genes OAS, MxA, APOBEC3G, and SLPI. However, viral ssRNA did not increase expression of the antimicrobial factors HBD1 or HBD2, showing this to be a specific antiviral response. In the present study, we found that at the mRNA level, a moderate yet significant IL-6, IL-8, type I interferon, and antiviral response occurred. At the protein level, both IL-6 and IL-8 secretion by the trophoblast was increased approximately 2-to 3-fold. In other tissues and cells at the maternalfetal interface, the response to the same concentration of viral ssRNA is dramatically different in terms of profile and magnitude. Normal term human fetal membranes generate a stronger secretion of IL-6 when compared to the trophoblast (IL-8 secretion is not upregulated, however); a number of other cytokines/chemokines are increased as well [36] . Furthermore, viral ssRNA does not induce the expression of IFNB or antiviral genes in human fetal membranes [36] . In contrast, human endometrial endothelial cells (HEECs) generate an IL-6 and IL-8 secretory response similar to that of the trophoblast as well as other cytokines and chemokines [35] . Moreover, the ssRNA-induced antiviral response in the HEECs is more restricted, with only IFNA, IFNB, MxA, and APOBEC3G being upregulated, but the response is much more robust than that seen in the trophoblast [35] . Thus, viral ssRNA exerts a differential response at the maternal-fetal interface, with the maternal side seemingly able to produce a stronger antiviral response than the placental side. This could account for why viral infections may be associated with adverse pregnancy outcomes.
We next sought to further examine the underlying mechanism involved in the trophoblast response to viral ssRNA. Using human first-trimester trophoblast cell lines expressing either TLR8-DN or MyD88-DN, we found that viral ssRNA induced the gene expression of IL6, IL8, IFNA, and SLPI through activation of the TLR8/MyD88 pathway. Interestingly, while trophoblast IL-6 secretion after exposure to viral ssRNA was TLR8/MyD88-dependent, IL-8 secretion appeared to be regulated by an alternative pathway. Indeed, IL-8 mRNA expression and protein secretion are differentially regulated. NFjB activation is essential for IL-8 mRNA expression, without promoting high levels of secretion. Additional signals, such as JNK, ERK, and P38 MAPK, are necessary for inducing high levels of IL-8 secretion [56] . Thus, blocking trophoblast TLR8 and MyD88 function may only inhibit the signals required for IL-8 gene transcription. Similarly, viral ssRNA-induced IFNB and the interferon-inducible antiviral factors OAS, MxA, and APOBE3G were also upregulated independent of TLR8 and MyD88, again indicating that viral ssRNA is able to trigger another signaling pathway. In a study using human fetal membrane explants, we observed similar MyD88-dependent and -independent cytokine/chemokine responses to viral ssRNA [36] . Having shown that IFNB production after exposure to viral ssRNA is not mediated by TLR8, we next examined the subsequent apoptotic response. Previously, we demonstrated that that viral ssRNA-induced IFNb was responsible for the subsequent apoptotic response. This inflammatory-induced cell death has also been reported in the trophoblast after exposure to cytomegalovirus via TNFa production [53, 55] . Similar to the interferon response, viral ssRNA-induced trophoblast apoptosis was also unaffected when the TLR8/MyD88 pathway was disabled.
In addition to human TLR8 and mouse TLR7 [39] , viral ssRNA can activate other pattern recognition receptors. Nod2 has been shown to mediate ssRNA-induced IRF-3 activation and IFNb production [57] ; however, the HTR8 trophoblast cell line used in our studies lacks this receptor [58] . Influenza virus can induce antiviral cytokines in human lung epithelial cells through the cytoplasmic RNA helicase, retinoic acid-inducible protein I (RIG-I), rather than TLR7/8 [59] , and direct activation of RIG-1 by viral ssRNA has been demonstrated [60] . Therefore, RIG-1 may be a candidate for the alternative pathway triggered by viral ssRNA in the trophoblast, leading to IFNb, and the subsequent antiviral and apoptotic response. This alternative signaling pathway may also be responsible for the regulation of IL-8 protein secretion by viral ssRNA.
One limitation of the present study is use of the human firsttrimester trophoblast cell line, HTR8 [26] , rather than primary cultures. However, the advantage is that this cell line behaves similarly to primary cells isolated from first-trimester placental villi [27] [28] [29] and is the easiest cell line to work with when making stable plasmid-based transfections. Thus, the use of this cell line allows us to ask mechanistic questions that might not be possible with primary cells.
Our final objective was to examine the impact viral ssRNA has on pregnancy outcome using a mouse model. Herein, we demonstrated that viral ssRNA administered late in gestation did not trigger preterm birth and had no effect on uterus weight, fetal weight, or fetus numbers. However, viral ssRNA did have an impact on the placenta in a manner similar to that of human trophoblast cells in vitro [25] . Viral ssRNA triggered placental caspase-3 activity and cell loss, suggesting apoptosis. Viral ssRNA also upregulated placental expression of the proinflammatory cytokine IL-6 and the pro-inflammatory chemokine KC, which may explain the increased number of immune cells in these tissues, as well as the type I interferon IFNB, which may explain the increased caspase-3 activity [25] . In addition, viral ssRNA also upregulated placental expression of the type I interferon IFNA and the antiviral genes OAS, MxA, APOBEC3, and SLPI, similar to what we observed in the human trophoblast. Furthermore, the magnitude of the placental response to ssRNA in vivo was moderate, similar to that seen in the human trophoblast. Also in keeping with our in vitro data using human trophoblast cells, viral ssRNA did not alter the antimicrobial beta defensins, BD1 and BD2, further highlighting the specificity of this placental viral response. To our knowledge, only one other study has evaluated the impact of TLR7/8 activation on pregnancy outcome using a mouse model [41] . In that study, viral ssRNA was not used. Instead, mouse TLR7 was activated using the immune response modifier, imiquimod (R837), and TLR7/8 was activated using CL097, a derivative of the antiviral compound imidazoquinoline. Both of these compounds, in concert with our observations, failed to trigger preterm birth but did induce hypertension and placental cytokine expression (including IL6) and upregulated placental TLR7/8 expression levels. Based on these observations, the investigators concluded that TLR7/8 activation may play a role in the development of preeclampsia. This is in keeping with our observation that viral ssRNA induced immune cell infiltration and placental caspase-3 activity, because in the human, preeclampsia is associated with elevated inflammatory immune cell infiltration POTTER ET AL. and placental apoptosis [46, 47, [61] [62] [63] . Thus, even if an infectious agent does not induce preterm birth, the pregnancy may still be affected. Indeed, infection of pregnant mice with the herpes virus MHV-68 alone does not trigger preterm birth but instead induces developmental problems in the fetus in the absence of vertical transmission and sensitizes the pregnancy to bacterial components [18] . In our model, it is possible that alterations in gestational length or fetal development were not altered because of the late timing of viral ssRNA administration and the short exposure time. However, in a similar model using the Nod1 agonist bacterial iE-DAP, we did observe a reduction in fetal weight at doses that did not cause preterm birth [64] .
In summary, our studies suggest that viral ssRNA may compromise pregnancy by altering trophoblast survival and function through both TLR8 and non-TLR8 signaling pathways, leading to placental dysfunction and immune changes at the maternal-fetal interface.
